ArticleBMC neurology2021

Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel.

Ann-Marie Chapman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.